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http://dx.doi.org/10.1016/j.ccr.2013.04.027SUMMARYEpidermal growth factor receptor (EGFR) initiates a signaling cascade that leads to DNA synthesis and cell
proliferation, but its role in regulating DNA replication licensing is unclear. Here, we show that activated
EGFR phosphorylates the p56 isoform of Lyn, p56Lyn, at Y32, which then phosphorylates MCM7, a licensing
factor critical for DNA replication, at Y600 to increase its association with other minichromosome mainte-
nance complex proteins, thereby promoting DNA synthesis complex assembly and cell proliferation. Both
p56Lyn Y32 andMCM7 Y600 phosphorylation are enhanced in proliferating cells and correlated with poor sur-
vival of breast cancer patients. These results establish a signaling cascade in which EGFR enhances MCM7
phosphorylation and DNA replication through Lyn phosphorylation in human cancer cells.INTRODUCTION
MCM7 is amember of theminichromosomemaintenance (MCM)
proteins, which were originally identified through a yeast genetic
screen aimed to identify mutants defective in MCM (Maine et al.,
1984). The MCM proteins were subsequently found to be
expressed in all eukaryotic organisms and are critical for
licensing DNA replication in proliferating cells (Tye, 1999).
MCM proteins 2–7 are highly conserved from yeast to humans
and form a hexameric complex during the G1 phase, which is
then loaded onto the replication origin to form a prereplication
complex (pre-RC) that is indispensable for initiation of DNA repli-Significance
Overexpression of MCM7 is associated with various human
mechanisms that regulate its function remain unclear. Here, w
phosphorylation, which potentiates the downstream MCM7 Y
somemaintenance complex assembly and cancer cell prolifera
namely EGFR/ phospho-p56Lyn Y32/ phospho-MCM7 Y60
tion licensing in human cancers. This finding links a cell-surfac
DNA replication licensing, which is an important step for initia
796 Cancer Cell 23, 796–810, June 10, 2013 ª2013 Elsevier Inc.cation (Lei and Tye, 2001). Assembly of the MCM protein com-
plex is essential for cell survival and proliferation, and sup-
pressing expression of individual MCM proteins resulted in
compromised DNA replication (Shi et al., 2010; Tsuji et al.,
2006), possibly due to lack of stable hexameric MCM complex.
In addition to its role in initiation of replication, theMCM complex
has been shown to serve as a putative replication fork helicase,
melting DNA origins in preparation for replication (Ishimi, 1997;
Labib et al., 2000; Lee and Hurwitz, 2001; Yan et al., 1993).
Recent studies suggest that MCM2–MCM7 complex interacts
with cell division cycle 45 (CDC45) and GINS to form the
CDC45-MCM-GINS complex (Moyer et al., 2006), which iscancers and correlated with poor prognosis; however, the
e showed that EGFR enhances p56Lyn activity through Y32
600 phosphorylation and positively modulates minichromo-
tion. We thus identified a tyrosine phosphorylation cascade,
0, that links EGFR and Lyn in MCM7-mediated DNA replica-
e receptor, EGFR, and a nonreceptor tyrosine kinase, Lyn, to
ting cell proliferation.
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Kang et al., 2012). MCM2–MCM7 also forms a double-hexame-
ric complex during pre-RC formation, which may be potentially
required for the initiation of bidirectional replication forks in S
phase (Evrin et al., 2009; Gambus et al., 2011).
Deregulation of DNA replication machinery components
causes chromosome instability and tumorigenesis (Bergoglio
et al., 2002; Rajagopalan et al., 2004), and the oncogenic poten-
tial of MCM7deregulation has beenwell described (Luo, 2011). A
transgenic mouse model demonstrates that expression of exog-
enous MCM7 in the epidermis accelerates squamous cell carci-
noma development upon carcinogen challenge (Honeycutt et al.,
2006). Additionally, increased MCM7 copy number and protein
level are associated with prostate cancer relapse and metas-
tasis, and a prostate cancer cell line ectopically expressing
MCM7 exhibits increased proliferation and invasiveness (Ren
et al., 2006). Similarly, MCM7 serves as a proliferation marker
and is associated with tumorigenesis in various human cancers,
including oral squamous cell carcinoma, colorectal cancer,
ovarian cancer, glioblastoma, and esophageal carcinoma
(Facoetti et al., 2006; Feng et al., 2008; Kan et al., 2009; Nishihara
et al., 2008; Ota et al., 2011). MCM7 has recently been demon-
strated as a prognostic marker that predicts poor cancer patient
survival and a therapeutic target of non-small cell lung carci-
nomas (Toyokawa et al., 2011). Interestingly, MCM7 protein is
a critical target of some oncogenic (e.g., androgen receptor;
Shi et al., 2008) and tumor suppressor (e.g., integrin a7 and reti-
noblastoma; Han et al., 2010; Sterner et al., 1998) signaling path-
ways, implying that multiple layers of regulation may be involved
in MCM7 biology and its oncogenic properties.
Epidermal growth factor receptor (EGFR) initiates a signaling
cascade that leads to DNA synthesis and cell proliferation
upon activation, and EGFR pathways are frequently deregulated
in human cancers (Paez et al., 2004; Yarden, 2001). Previously,
our mass spectrum analysis detected members of MCM hex-
americ ring complex in the EGFR immunoprecipitates from
A431 cancer cells (Huo et al., 2010), thereby raising the possibil-
ity that EGFR signaling is functionally involved in DNA replication
licensing. Since MCM7 is critical in DNA replication and involved
in oncogenic signaling pathways, we set out to determine
whether MCM7 is a downstream target of EGFR signaling.
RESULTS
MCM7 Is Tyr Phosphorylated by Lyn Kinase
We first validated the interaction between EGFR and MCM pro-
teins by immunoprecipitation (IP)-western analysis and detected
MCM5 and MCM7 in the EGFR immunoprecipitates (Figure S1A
available online). Interestingly, the amount of MCM7 but not
MCM5 in the EGFR immunoprecipitates was increased with
EGF stimulation and decreased with the Tyr kinase inhibitor
gefitinib treatment (Figure S1B), suggesting that the association
between EGFR and MCM7 was dependent on EGFR kinase
activity and MCM7 might be a kinase substrate of EGFR or
EGFR downstream kinases.
Because Tyr phosphorylation carries significant biological
functions and it is unclear whether Tyr phosphorylation is
involved in MCM7 function in DNA replication licensing, we
investigated whether MCM7 is regulated by this posttransla-tional modification in proliferating cells. We examined MCM7
Tyr phosphorylation in a panel of cancer cell lines stimulated
with EGF using an anti-phosphoTyr antibody (4G10) and found
that MCM7 was Tyr phosphorylated to various degrees in all of
them except in MDA-MB-231 cells (Figures 1A and S1C). The
weaker MCM7 Tyr phosphorylation observed in Du145
compared with H266 cells is likely due to their lower EGFR
expression level (Figure S1C). Since MCM7 is functionally
involved in DNA synthesis and cell proliferation, the failure to
observe EGF-induced MCM7 Tyr phosphorylation in MDA-MB-
231 cells is consistent with the literature that MDA-MB-231 cells
lack proliferative response to EGF (Price et al., 1999). We then
asked whether MCM7’s phosphorylation status affects its ability
to associate with other MCM proteins. Interestingly, the kinetics
between MCM7 Tyr phosphorylation and its association with
MCM2 and MCM3 but not MCM4 were positively correlated
upon EGF stimulation (Figure 1B). In the absence of EGF, we
did not observe MCM7 Tyr phosphorylation or increased
MCM2 andMCM3 association (Figure S1D). These data suggest
that EGF-mediated Tyr phosphorylation of MCM7 regulates its
association with other MCM members.
Although MCM7 was detected in the EGFR immunoprecipi-
tates, MCM7 failed to be Tyr phosphorylated by recombinant
EGFR in an in vitro kinase assay (data not shown). To identify
the kinase that phosphorylates MCM7, we immunoprecipitated
MCM7 and subjected the complex to mass spectrometry anal-
ysis. Among 94 MCM7-interacting proteins identified, Lyn was
the only Tyr kinase (Table S1). The interaction between Lyn and
MCM7 was validated by reciprocal immunoprecipitation, and
Lyn was able to Tyr phosphorylate MCM7 when both proteins
are ectopically expressed (Figure 1C). EGF stimulation
increased the amount of endogenous MCM7 detected in Lyn
immunoprecipitates, which could be reduced by the Lyn kinase
inhibitor PP2, suggesting that the kinase activity of Lyn
enhances its interaction with MCM7 (Figure 1D, top). Further-
more, EGF-stimulated MCM7 Tyr phosphorylation was then
abolished by PP2 (Figure 1D, bottom), supporting Lyn as the
Tyr kinase for MCM7. Indeed, purified recombinant Lyn
kinase phosphorylated glutathione S-transferase (GST)-fused
MCM7 in vitro (Figure 1E). To verify whether Lyn phosphory-
lates MCM7 in vivo, we knocked down Lyn expression using
short interfering RNAs (siRNAs) and examined MCM7 Tyr
phosphorylation in response to EGF. Upon EGF stimulation,
siRNA targeting the 30 UTR of Lyn but not other members of
Src family kinases (Src, Yes, and Fyn) diminished MCM7 Tyr
phosphorylation, which was rescued by reintroduction of a
siRNA-resistant Flag-p56Lyn (Figure 1F). Small hairpin RNA
targeting the protein coding region of Lyn also diminished the
MCM7 Tyr phosphorylation (Figure S1E), and MCM7 was
detected in the Lyn but not Src, Fyn, or Yes immunoprecipi-
tates (Figure S1F). Lyn exists as two isoforms, p53Lyn and
p56Lyn (Yamanashi et al., 1991). Although both p56Lyn and
p53Lyn interacted with MCM7 (Figure S1G), the kinase activity
of p56Lyn but not p53Lyn toward MCM7 was potentiated upon
EGF stimulation (Figure S1H), suggesting p56Lyn is the likely
physiological Tyr kinase for MCM7 in response to EGF treat-
ment in vivo. Taken together, these results demonstrate that
Lyn Tyr phosphorylates MCM7 in vivo and that this event is
EGF dependent.Cancer Cell 23, 796–810, June 10, 2013 ª2013 Elsevier Inc. 797
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Figure 1. MCM7 Is Tyr phosphorylated by Lyn Kinase
(A) Immunoprecipitates of endogenous MCM7 were analyzed by western blotting using 4G10 antibody for detecting Tyr phosphorylation in various cancer cell
lines stimulated with EGF for 1 hr.
(B)Western blot of endogenousMCM2,MCM3, andMCM4 in anti-MCM7 immunoprecipitates fromA431 cells stimulatedwith EGF at various time points. The cell
lysate fromA431 cells treatedwith EGF for 2 hr was used for both the anti-MCM7 and control immunoglobulin G (IgG) immunoprecipitation. The right graph shows
quantified densities of bands at different time points, and the band’s density in control lane (i.e., EGF 0 hr) was set as 1.
(C) Cell lysates from 293T cells expressing exogenous Myc-MCM7 and Flag-p56Lyn were subjected to immunoprecipitation and immunoblotting with indicated
antibodies.
(D) A431 cell lysates with different treatments were subjected to immunoprecipitation and immunoblotting with indicated antibodies to detect the association of
endogenous MCM7 with Lyn and MCM7 Tyr phosphorylation.
(E) Western blot of Tyr phosphorylation of GST-MCM7 by recombinant p56Lyn (top) and phosphorylation of p56Lyn itself (middle) using 4G10 antibody. Bottom:
Coomassie Blue staining of the GST-MCM7 input.
(F) Western blot of endogenous MCM7 Tyr phosphorylation in A431 cells with or without EGF stimulation (lanes 3 and 2). Endogenous Lyn was knocked down by
siRNA (targeting 30 UTR; lane 4) and rescued with a siRNA-resistant Flag-Lyn (lane 5).
See also Figure S1 and Table S1.
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To further validate the MCM7 Tyr phosphorylation and identify
corresponding site(s), we used mass spectrometry to analyze
endogenous MCM7 immunopurified from EGF-stimulated
A431 cells and identified a peptide containing phosphorylated
Y600 of MCM7 (Figure 2A). The MCM7 Y600 sequence matched
the consensus sequence phosphorylated by Src family kinases
(Olsen et al., 2006), and Lyn was predicted as the putative kinase798 Cancer Cell 23, 796–810, June 10, 2013 ª2013 Elsevier Inc.that phosphorylates MCM7 at Y600 (NetworKIN). Indeed, an
in vivo Tyr phosphorylation assay demonstrated that it was not
EGFR but Lyn that enhanced Tyr phosphorylation of MCM7
(Figure 2B, lanes 1–3). In the presence of EGFR, p56Lyn-medi-
ated MCM7 phosphorylation was significantly augmented,
suggesting that EGFR signaling potentiates p56Lyn kinase
activity for MCM7 phosphorylation. Importantly, a kinase-dead
(KD) p56Lyn mutant (Kasahara et al., 2004) was unable to
Cancer Cell
EGFR Potentiates MCM7 Function through Lyn Kinasephosphorylate MCM7 (lane 4 versus lane 6) and p56Lyn did not
phosphorylate the MCM7 Y600F mutant (lane 4 versus lane 5).
Similarly, purified recombinant p56Lyn kinase phosphorylated
GST-MCM7 but not the GST-MCM7 Y600F (Figure 2C), indi-
cating that Lyn phosphorylates MCM7 at Y600.
To facilitate the detection of MCM7 Y600 phosphorylation, we
generated a polyclonal antibody that recognized Y600-phos-
phorylated MCM7. This antibody recognized ectopic MCM7
coexpressed with p56Lyn but not MCM7 alone or MCM7 Y600F
coexpressed with p56Lyn in 293T cells (Figure S2A) and was
used to verify MCM7 Y600 phosphorylation in vivo. In A431 cells,
EGF induced phosphorylation of MCM7 Y600 (Figure 2D, lane 3
versus lane 2). Knockdown of endogenous Lyn protein by siRNA
diminished MCM7 Y600 phosphorylation (lane 4), which was
rescued by reintroduction of a siRNA-resistant Flag-p56Lyn
(lane 5), supporting that Lyn phosphorylates MCM7 at Y600
upon EGF stimulation. We also observed EGF-induced MCM7
Y600 phosphorylation in six other cancer cell lines (Figure S2B).
Because MCM7 is important for licensing DNA replication and
Lyn phosphorylates MCM7 upon EGF stimulation, we examined
whether Lyn regulated MCM7 function in DNA replication
licensing upon EGF stimulation. Indeed, knockdown of the
endogenous Lyn protein by two different siRNAs compromised
the EGF-induced loading of MCM2, MCM3, and MCM7 onto
the chromatin (Figures 2E and S2C) and the replication origins
in the LMNB2 (lamin B2) and MCM4 locus measured by chro-
matin IP (ChIP)–quantitative PCR (qPCR) analysis (Figures 2F
and S2D). These evidences suggest that Lyn-mediated Y600
phosphorylation may regulate MCM7 function in DNA replication
licensing.
MCM7 Y600 Phosphorylation Enhances MCM Complex
Assembly and Cancer Cell Proliferation
We then examined if MCM7 Y600 was also involved in cancer
cell proliferation and generated MDA-MB-468 breast cancer
cells expressing Myc-tagged MCM7 (468-MCM7), MCM7
Y600F (468-Y600F), or control vector (468-vector) for functional
studies. MDA-MB-468 cells were chosen because Lyn was
required for MCM7 phosphorylation (Figure S1E) and Lyn knock-
down significantly compromised their proliferation (Figure S3A).
Consistent with a previous study (Ren et al., 2006), ectopic
expression of MCM7 enhanced cell proliferation and DNA syn-
thesis rate of MDA-MB-468 cells (Figures 3A and 3B, lane 2
versus lane 1). Comparedwith 468-MCM7cells, 468-Y600F cells
showed decreased cell proliferation andDNA synthesis rate (Fig-
ure 3A and 3B, lane 3 versus lane 2). In addition, cell proliferation
(Figure 3A, lane 4 versus lane 2) and DNA synthesis rate (Fig-
ure 3B, lane 4 versus lane 2) were decreased in 468-MCM7 cells
treated with PP2. Furthermore, in an orthotopic breast cancer
mouse model, 468-Y600F mammary tumor grew slower than
did 468-MCM7 tumors (Figure 3C). MCM7 also enhanced the
proliferation of H226 and A431 cells more significantly than did
MCM7 Y600F (Figure S3B). Collectively, these results suggest
that Y600 phosphorylation is involved in the MCM7-mediated
DNA replication and cancer cell proliferation.
We further examined whether phosphorylation of Y600
enhances MCM7 interaction with other MCMmembers. Indeed,
EGF stimulation enhanced association of Myc-MCM7 with
MCM2, MCM3, and MCM5, which was decreased in cellstreated with PP2 (Figures 3D and S3C). In contrast, Myc-
MCM7 Y600F exhibited a much weaker interaction with other
MCM proteins (Figure 3D). It should be mentioned that, similar
to the endogenous MCM7 (Figure 1B), Myc-MCM7 interacted
with MCM2 without EGF (Figure S3D). We in addition used a
phosphomimetic mutant MCM7 Y600E to determine whether
the requirement of Lyn in MCM7 interaction with other MCM
members could be bypassed. Indeed, in cells cultured in a
low-serum medium to prevent EGFR activation, MCM7 Y600E
interacted with other MCM members stronger than did MCM7
andMCM7Y600F (Figure S3E). Furthermore, ectopic expression
ofMCM7Y600E but notMCM7Y600F rescued the EGF-induced
DNA synthesis compromised by Lyn knockdown (Figure S3F).
These data suggest that MCM7 Y600 phosphorylation is critical
for the MCM complex assembly and DNA synthesis initiated by
the EGFR-Lyn signaling axis.
Assembled MCM complex loads onto the replication origins
on the chromatin to license DNA replication. Therefore, we
examined whether the association of MCM members on the
chromatin was enhanced upon EGF stimulation. Indeed, EGF
stimulation increased chromatin loading of MCM7 together
with MCM2, MCM3, and MCM5; however, EGF-induced chro-
matin loading ofMCM7Y600Fwas barely detectable (Figure 3E).
We then performed ChIP–qPCR analysis of MCM7 or MCM7
Y600F binding to the DNA replication origins in the MCM4 and
LMNB2 loci upon EGF stimulation to determine the functional
important of MCM7 Y600 in DNA replication licensing. Indeed,
Y600 phosphorylation enhanced MCM7-mediated DNA replica-
tion licensing, where EGF induced the loading of theMyc-MCM7
but not Myc-MCM7 Y600F onto the DNA replication origins (Fig-
ure 3F). Neither MCM7 nor MCM7 Y600F mutant exhibited
increased binding to a control locus that did not contain a repli-
cation origin (2 kb downstream of LMNB2 locus) upon EGF stim-
ulation (Figure 3F). Consistently, EGF induced the loading of the
endogenous MCM2, MCM3, and MCM7 onto the DNA repli-
cation origins much more significantly in cells expressing
Myc-MCM7 than those expressing MCM7 Y600F (Figure S3G),
suggesting that Y600 phosphorylation aids in complex assembly
at the DNA replication origins upon EGF stimulation.
To determinewhether Y600phosphorylation is critical for EGF-
induced DNA synthesis, we used a siRNA to knockdown endog-
enousMCM7 in cells expressing the siRNA-resistantMyc-MCM7
or Myc-MCM7 Y600F and examined their responses to EGF-
induced DNA synthesis and cell cycle progression. Consistently,
EGF-induced DNA synthesis was higher in cells expressing
Myc-MCM7 than in cells expressing Myc-MCM7 Y600F (Fig-
ure 3G). Furthermore, 12 hr of EGF treatment allowed 20%
(45%–25%) of Myc-MCM7-expressing cells but only 8%
(34%–26%) of Myc-MCM7 Y600F-expressing cells to progress
through G1 phase (Figure 3H). We also used untagged MCM7
and MCM7 Y600F to perform the DNA synthesis assay in cells
with endogenous MCM7 knockdown, and consistently, the
EGF-induced DNA synthesis was much more significant in cells
expressing MCM7 than cells expressing MCM7 Y600F (Fig-
ure S3H). A bromodeoxyuridine (BrdU) pulse-chase approach
was also used to evaluate the cell cycle progression of MCM7
andMCM7 Y600F cells. After BrdU labeling in S phase, the num-
ber of BrdU+ cells in G1 phase for MCM7 cells was increased
more significantly thanMCM7Y600F cells at 9 hr and 12 hr chaseCancer Cell 23, 796–810, June 10, 2013 ª2013 Elsevier Inc. 799
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Figure 2. Lyn Phosphorylates MCM7 at Y600
(A) Mass spectrometry analysis of endogenous MCM7 immunopurified from A431 cells.
(B) Western blot of Tyr phosphorylation of MCM7 or MCM7 Y600F from 293T cells transfected with EGFR, Flag-p56Lyn, and Myc-MCM7, as indicated. The
number under each band is quantified relative density, with lane 3 being set as 1.
(C) Western blot analysis of Tyr phosphorylation of GST-MCM7 and GST-MCM7 Y600F by recombinant p56Lyn kinase (top) and phosphorylation of p56Lyn using
4G10 antibody (middle). Bottom: Coomassie Blue staining of the GST fusion protein input.
(D) Western blot of phosphorylation of the endogenous MCM7 Y600 in A431 cells with or without EGF stimulation (lanes 3 and 2). Endogenous Lyn was knocked
down by siRNA (targeting 30 UTR; lane 4) and rescued with a siRNA-resistant Flag-p56Lyn (lane 5). The number under each band is quantified relative density, with
lane 3 being set as 1.
(legend continued on next page)
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EGFR Potentiates MCM7 Function through Lyn Kinasetime points, suggesting that MCM7 cells have a shorter cell cycle
time than MCM7 Y600F cells (Figures S3I and S3J). Taken
together, these observations suggest a pathway in which phos-
phorylation of MCM7 Y600 by Lyn kinase enhances MCM com-
plex assembly andDNA replication licensing in proliferating cells.
EGFR Phosphorylates p56Lyn at Y32
To identify potential regulators of Lyn activation after EGF stim-
ulation, endogenous Lyn was immunoprecipitated and the 4G10
antibody was used to detect Tyr-phosphorylated Lyn-associ-
ated proteins. A single 175 kDa Lyn-interacting protein, for which
the Tyr phosphorylation relied on EGF stimulation, was detected
(starred, Figure 4A). Since EGFR itself is 175 kDa, we examined
whether EGFR interacts with Lyn in response to EGF stimulation.
Indeed, coimmunoprecipitation analyses in A431 cells detected
EGFR in the Lyn immunoprecipitates, which increased with EGF
and decreased with two different EGFR kinase inhibitors,
AG1478 and gefitinib (Figure 4B), suggesting that Lyn interacted
with activated EGFR.
To further investigate how EGFR regulates Lyn, EGFR was
immunoprecipitated and both p56Lyn and p53Lyn were detected.
Moreover, EGF stimulation significantly increased the amount of
p56Lyn (Figure 4C). Interestingly, EGFR kinase inhibitors dimin-
ished the amount of p56Lyn but not p53Lyn in the EGFR immuno-
precipitates (Figure 4C). The interaction between EGFR and
p56Lyn but not p53Lyn was dependent on EGFR kinase activity,
suggesting that p56Lyn is a kinase substrate for EGFR. Indeed,
purified recombinant EGFR phosphorylated a GST fusion of
the domain unique to p56Lyn that contained only one Tyr residue,
Y32 (Figure 4D, lower left panel), and substitution of Y32with Phe
abolished the EGFR-mediated phosphorylation (Figure 4D,
lower right panel). Furthermore, recombinant EGFR phosphory-
lated kinase-dead GST-p56Lyn but not kinase-dead GST-p56Lyn
Y32F (Figure 4E). Since Y32 does not exist in p53Lyn (Figure 4D,
upper panel; Yamanashi et al., 1991), this result is consistent with
our observation that EGFR kinase inhibitors diminished the asso-
ciation of EGFR with p56Lyn but not p53Lyn (Figure 4C). To facil-
itate detection of p56Lyn Y32 phosphorylation, we generated a
polyclonal antibody that specifically recognizes Y32-phos-
phorylated p56Lyn. This antibody recognized ectopic p56Lyn
coexpressed with EGFR but not p56Lyn alone or p56Lyn Y32F
coexpressed with EGFR in 293T cells (Figure S4). Thus, we
used this antibody to detect p56Lyn Y32 phosphorylation in vivo.
Phosphorylation of p56Lyn Y32 was significantly increased upon
EGF stimulation but diminished by EGFR kinase inhibitors (Fig-
ure 4F). These results indicate that EGFR phosphorylates
p56Lyn at Y32 in response to EGF stimulation.
Phosphorylation of Y32 Enhances p56Lyn-Mediated
MCM7 Tyr Phosphorylation and Cell Proliferation
Next, we investigated whether phosphorylation at p56Lyn Y32 is
important for DNA synthesis and cancer cell proliferation. MDA-(E) Cell lysates from A431 cells transfected with the indicated siRNA with or wit
MCM2, MCM3, and MCM7 in the soluble fraction or chromatin fraction.
(F) ChIP analysis of endogenous MCM2, MCM3, and MCM7 binding to the D
downstream of LMNB2 locus) in A431 cells transfected with the indicated siRNA
cells without EGF stimulation (n = 3). Error bars show ±SD.
See also Figure S2.MB-468 cells stably expressing p56Lyn Y32F (468-Y32F)
exhibited decreased cell proliferation (Figure 5A) and DNA syn-
thesis rate (Figure 5B) compared with those expressing p56Lyn
(468-Lyn), and these results are similar to MDA-MB-468 cells
expressing MCM7 Y600F (Figures 3A and 3B). When treated
with gefitinib or AG1478, which abolished the Lyn Y32 phosphor-
ylation (Figure 4F), 468-Lyn cells exhibited compromised cell
growth and DNA synthesis similar to 468-Y32F cells (Figures
5A and 5B). In an orthotopic breast cancer mouse model, 468-
Y32F-induced mammary tumor grew slower than did 468-Lyn
cells (Figure 5C), which is comparable to the 468-MCM7
Y600F cells (Figure 3C). These results collectively suggest that
Y32 phosphorylation is critical for the p56Lyn function. In support
of this notion, EGF-induced Lyn Y397 phosphorylation, which
has been shown to enhance Lyn’s kinase activity (Ingley, 2012;
Figure 5D, top), and MCM7 Y600 phosphorylation (Figure 5D,
middle) were clearly observed after 60 min EGF stimulation in
p56Lyn cells, while barely detectable in p56Lyn Y32Fmutant cells.
Similarly, immunofluorescence analysis using confocal micro-
scopy demonstrated that p56Lyn is associated with more robust
Lyn Y397 phosphorylation compared with p56Lyn Y32F mutant
(Figure S5A).
To show that Y32 phosphorylation is critical for p56Lyn function
in MCM7 phosphorylation, we used a phosphomimetic mutant
p56Lyn Y32E to determine whether the requirement of EGFR acti-
vation in Lyn-dependent MCM7 phosphorylation could be
bypassed. Indeed, in cells cultured with a low-serum medium
to prevent EGFR activation (Figure S5B, right), ectopic expres-
sion of p56Lyn Y32E but not p56Lyn significantly induced MCM7
Tyr phosphorylation that was associated with increased interac-
tion with other MCM members (Figure S5B, left). Interestingly,
p56Lyn Y32E interacted with MCM7 much more significantly
than p56Lyn (Figure S5B, left). Collectively, these data suggest
a cascade in which EGFR-mediated p56Lyn Y32 phosphorylation
regulates the downstream MCM7 Y600 phosphorylation and
DNA synthesis.
p56Lyn Y32 andMCM7 Y600 Phosphorylation Correlates
with Physiological Proliferation
To investigate the biological importance of the EGFR/p56Lyn/
MCM7/DNA replication licensing cascade in cells with physio-
logical EGFR level, we first examined these events in regenerat-
ing liver. Liver regeneration is a well-established physiological
model for DNA synthesis and cell proliferation and requires
EGFR (Bucher, 1991; Natarajan et al., 2007). After a partial hep-
atectomy, robust DNA replication indicated by increased prolif-
erating cell nuclear antigen and MCM7 protein expression
ensued within 24 hr (Figure 6A, bottom). The increase in the
MCM7 level was associated with prominent Y600 Tyr phosphor-
ylation, suggesting that Lyn was activated in regenerating liver.
Similarly, phosphorylation of p56Lyn Y32 as well as association
of p56Lyn with MCM7 was increased in the regenerating liverhout EGF stimulation were subjected to western blot analysis of endogenous
NA replication origins in LMNB2 (lamin B2), MCM4, and control locus (2 kb
and stimulated with or without EGF for 7 hr. Results are normalized to levels in
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Figure 3. MCM7 Y600 Phosphorylation Enhances MCM Complex Assembly and Cancer Cell Proliferation
(A) MDA-MB-468 (13 104) cells carrying the indicated constructs were seeded in the presence or absence of 1 mMPP2, and cell number was determined at day 7
(n = 3).
(B) MDA-MB-468 cells were treated as (A), and DNA synthesis rate was assayed at day 5 by detection of BrdU incorporation (n = 3).
(C) In vivo tumor growth of orthotopically transplanted MDA-MB-468 cells (n = 5).
(D)Western blot of endogenousMCM2,MCM3, andMCM5 in the anti-Myc-MCM7 immunoprecipitates from the soluble fraction of A431 cells with or without EGF
stimulation.
(legend continued on next page)
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EGFR Potentiates MCM7 Function through Lyn Kinase(Figure 6A, top). We in addition examined whether this cascade
is associated with proliferation of normal mammary epithelial
cells expressing physiological level of EGF, using MCF-10A cells
as a model. It is well established that the survival and prolifera-
tion of MCF-10A cells relies on EGF and that EGF induces cell
cycle progression of MCF-10A cells synchronized at G0 phase
(LeVea et al., 2004; Figure S6A). Upon EGF stimulation, phos-
phorylation of EGFR Y1173, p56Lyn Y32, and MCM7 Y600
were simultaneously induced and the level of p56Lyn Y32 and
MCM7 Y600 phosphorylation persisted from 8 to 24 hr (Fig-
ure 6B). Since MCM7 Y600 phosphorylation is involved in its
association with other MCMmembers, these results are consis-
tent with the current model that MCM complex assembly begins
during the G1 phase (Lei and Tye, 2001). As expected, we found
that Lyn and MCM7 associate upon EGF stimulation (Figure 6C)
and EGFR or Lyn kinase activity is required for the EGF-induced
MCF-10A cell proliferation (Figure 6D). EGF also induced prolif-
eration of human cancer cell line NCI-H226 and triggered
p56Lyn Y32 and MCM7 Y600 phosphorylation (Figure 6E). It
has been shown that, when A431 cells are seeded at low density,
lower concentrations (3–100 pM) rather than higher concentra-
tions of EGF induce their proliferation (Kawamoto et al.,
1983). Consistently, we found 100 pM EGF enhanced A431 cell
proliferation and triggered Lyn Y32 and MCM7 Y600 phosphor-
ylation (Figure S6B). Taken together, our findings demonstrate a
biological importance for phosphorylation of p56Lyn Y32 and
MCM7 Y600 in cell proliferation.
p56Lyn Y32 and MCM7 Y600 Phosphorylation Correlate
with EGFR Status in Human Tumor Samples and Poor
Survival of Breast Cancer Patients
To determine the pathological relevance of this signal pathway in
human cancers, we analyzed the relationship between EGFR,
phosphorylation of p56Lyn Y32, and MCM7 Y600 in human
breast tumor samples using immunohistochemistry (IHC) stain-
ing. Specificity of the antiphosphorylation antibodies for IHC
staining was verified by demonstrating that the anti-phospho
p56Lyn Y32 or anti-phosphoMCM7Y600 staining can be neutral-
ized with the corresponding tyrosine-phosphorylated peptide
but not with the nonphosphorylated peptide (Figure S7A). Signif-
icantly, EGFR expression level was associated with Tyr phos-
phorylation level of p56Lyn Y32 and MCM7 Y600 (Figures 7A
and 7B). Additionally, Tyr phosphorylation level of MCM7 Y600
was correlated with the level of proliferation marker Ki-67. In
the tumors with low (/+) p-MCM7 level, only 44% (35/79) of
them were identified as having the highest Ki-67 level (+++). In
the tumors with higher p-MCM7 level (++ and +++), the samples
identified as the highest Ki-67 level (+++) were significantly
increased to 71% (10/14) and 75% (6/8), respectively (Figures(E) Same as (D), except binding of MCM7 with other MCM members in chromati
(F) ChIP analysis of Myc-MCM7 or Myc-MCM7 Y600F binding to the DNA replicat
LMNB2 locus) in A431 cells stimulated with EGF for 7 hr. Results are normalized
(G) Top: HeLa cells expressing siRNA-resistant Myc-MCM7 orMyc-MCM7Y600F
indicated. After 3 days, cells were lysed and subjected to western blot analysis u
were seeded in the presence or absence of 10 ng/ml EGF, and DNA synthesis ra
(H) HeLa cells expressing siRNA-resistant Myc-MCM7 or Myc-MCM7 Y600F we
48 hr of serum starvation and then stimulated with EGF for 12 hr. Cell cycle prog
Error bars show ±SD.
See also Figure S3.7C and 7D). These data suggested that MCM7 Y600 phos-
phorylation was pathologically associated with cancer cell
proliferation. We also observed that Lyn and MCM7 protein
levels were correlated with Ki-67 expression, suggesting their
potential contributions to cell proliferation in breast tumors
(Figure S7B).
To determine the pathological relevance of p56Lyn activation
and MCM7 Y600 phosphorylation, we analyzed the relationship
between phosphorylation of p56Lyn Y32 and MCM7 Y600 in
human breast tumor samples and lung cancer tissue arrays
using IHC staining. Significantly, phosphorylation of p56Lyn Y32
was correlated with phosphorylation of MCM7 Y600 in human
breast (p < 0.02) (Table S2) and lung cancers (p = 0.003) (Table
S3). To verify Lyn is the Tyr kinase that phosphorylates MCM7
at Y600 in human tumor samples, we performed IHC staining
in tissue microarrays of human lung and breast cancers. Expres-
sion of Lyn but not other Src family kinases (Src, Yes, Fyn, and
Lck) was significantly correlated with the phosphorylation level
of MCM7 Y600 in both human lung tumor tissues (p < 0.001)
(Table S4; Figure S7C) and breast tumor tissues (p = 0.002)
(Table S5).
We next sought to determine whether the levels of phospho-
Lyn Y32 and phospho-MCM7 Y600 expression correlated with
survival of breast cancer patients. We found that the overall sur-
vival of breast cancer patients whose cancers had high level of
phospho-Lyn Y32 was worse than patients whose cancers had
low level of phospho-Lyn Y32 (p = 0.037; Figure 7E). Similarly,
overall survival of breast cancer patients whose cancers had
high level of phospho-MCM7 Y600 was worse than patients
whose cancers had low level of phospho-MCM7 Y600 (p =
0.035; Figure 7F). Multivariate survival analysis using Cox’s
regression model suggested that both phospho-Lyn Y32 and
phospho-MCM7 Y600 were independently correlated with over-
all survival in the breast cancer patients (Figure S7D). Addition-
ally, overall survival of the breast cancer patients whose cancers
had high levels of both phospho-Lyn Y32 and phospho-MCM7
Y600 was much worse than patients in all other categories (p =
0.003; Figure S7E). Taken together, these findings provide a sig-
nificant pathological relevance for phosphorylation of p56Lyn Y32
and MCM7 Y600 in human cancers.
DISCUSSION
Deregulated MCM7 expression can increase cancer cell prolifer-
ation and contribute to tumorigenesis; however, how specific
oncogenic pathways regulate MCM7 functions is not well under-
stood. Here, we show that Lyn-mediated MCM7 Y600 phos-
phorylation increases MCM7’s association with other MCM
members, consequently enhancing DNA synthesis and celln fraction was assessed.
ion origins in LMNB2 (lamin B2),MCM4, and control locus (2 kb downstream of
to levels in cells without EGF stimulation (n = 5).
were transfectedwith a control siRNA or a siRNA targeting 30 UTR ofMCM7, as
sing the indicated antibodies. Bottom: after siRNA transfection, 1 3 104 cells
te was assayed at day 3 by detection of BrdU incorporation (n = 3).
re transected with siRNA targeting MCM7 30 UTR. Cells were synchronized by
ression was analyzed by PI staining using fluorescence-activated cell sorting.
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Figure 4. EGFR Phosphorylates p56Lyn Y32
(A) Anti-Lyn immunoprecipitates from A431 cells with or without EGF stimulation were analyzed by western blotting using 4G10 antibody. The asterisk indicates
the protein phosphorylated by EGF stimulation in the anti-Lyn immunoprecipitates.
(B) Western blot of endogenous EGFR and phospho-EGFR Y1173 (EGFR p-Y1173) in the anti-Lyn immunoprecipitates from A431 cells with indicated treatments.
(C) Western blot of endogenous Lyn in the anti-EGFR immunoprecipitates from A431 cells with different treatments. The number above (for p56Lyn) or under (for
p53Lyn and EGFR) each band is quantified relative density, with lane 2 being set as 1.
(legend continued on next page)
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AC D
B
Figure 5. Phosphorylation of Y32 Enhances p56Lyn-Mediated MCM7 Tyr Phosphorylation and Cancer Cell Proliferation
(A) MDA-MB-468 cells (13 104) carrying indicated constructs were seeded in the presence or absence of 500 nM inhibitors. Cell number was determined at day 7
(n = 3).
(B) DNA synthesis rate of MDA-MB-468 cells treated as (A) was assayed at day 5 by detection of BrdU incorporation (n = 3).
(C) In vivo tumor growth of orthotopically transplanted MDA-MB-468 cells (n = 5).
(D) Western blot of p56Lyn Y397 andMCM7 Y600 phosphorylation in Lyn knockdown A431 cells expressing Flag-p56Lyn Y32F or Flag-p56Lyn stimulated with EGF
at indicated time point. Error bars show ±SD.
See also Figure S5.
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EGFR Potentiates MCM7 Function through Lyn Kinaseproliferation. Furthermore, the activity of p56Lyn is upregulated
via Y32 phosphorylation by EGFR, resulting in potentiation of
MCM7 Y600 phosphorylation. In human breast cancer, phos-
phorylation of both p56Lyn Y32 and MCM7 Y600 correlate with
EGFR expression level in tumor samples and with poor survival
of patients. Thus, we propose a Tyr phosphorylation cascade
triggered by EGFR for licensing DNA replication in proliferating
cells, which is augmented in cancer cells with deregulated
EGFR activity. These findings suggest that Lyn may be a critical
EGFR downstream mediator in licensing DNA replication and(D) Western blot detection of Tyr phosphorylation of GST fused various domains o
each blot. A schematic representation of Lyn isoforms with the 21-amino acid pre
domain; U/Y32F, the U domain with Y32F mutation.
(E)Western blot of Tyr phosphorylation of GST-p56Lyn KD andGST-p56Lyn KD/Y32
4G10 antibody. Bottom: GST-p56Lyn KD and GST-p56Lyn KD/Y32F detected by
(F) Cell lysates of A431 cells with different treatments were subjected to anti-Lyn
(p56Lyn p-Y32) antibody.
See also Figure S4.therefore may be a promising therapeutic target in treating
EGFR-activated cancers.
Although the therapeutic efficacy of pan-Src family kinase
inhibitors is currently being evaluated in the clinic, the Lyn-spe-
cific inhibitor is not yet available for treatment of human cancers.
Together with the previous reports in prostate cancer (Golden-
berg-Furmanov et al., 2004; Park et al., 2008), this study further
identifies Lyn as a therapeutic target in breast and lung cancers.
It is worthwhile to mention that EGFR Tyr kinase inhibitors (TKIs),
such as erlotinib and gefitinib, are well-established therapeuticsf p56Lyn by recombinant EGFR in vitro. Coomassie blue staining is shown below
sented in p56Lyn but not in p53Lyn indicated is shown at the top. U, the unique
F by recombinant EGFR (middle) and phosphorylation of EGFR itself (top) using
western blot using an anti-GST antibody.
immunoprecipitation and then immunoblotted with the phospho-p56Lyn Y32
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Figure 6. Phosphorylation of p56Lyn Y32 and MCM7 Y600 Correlate
Physiological Proliferation
(A) Tyr phosphorylation of p56Lyn Y32 andMCM7 Y600 in regenerating liver. N,
normal liver; R, regenerating liver 24 hr after partial hepatectomy.
(B) MCF-10A cells were serum starved for 48 hr and then stimulated with EGF
at the indicated time points. Lysates were immunoblotted with indicated
antibodies. The number under each band of anti-phospho MCM7 Y600
(MCM7 p-Y600) blot is quantified relative density, with the lane 1 (0 hr) being
set as 1.
(C) Lysates of MCF-10A cell treated with EGF for 8 hr were subjected to Lyn
immunoprecipitation and immunoblotting with indicated antibodies.
(D) MCF-10A cells were serum starving for 48 hr and then stimulated with EGF
in the presence of indicated inhibitors. Cell number was determined 48 hr after
EGF stimulation (n = 3).
(E) In the top panel, 1 3 104 NCI-H226 cells were seeded in the presence or
absence of 50 ng/ml EGF in medium with 0.5% calf serum, and cell number
was determined at day 5 (n = 3). In the bottom panel, NCI-H226 cells were
untreated or treated with 50 ng/ml EGF for 4 hr, and the lysates were
immunoblotted with the indicated antibodies. Error bars show ±SD; **,
p < 0.01.
See also Figure S6.
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EGFR Potentiates MCM7 Function through Lyn Kinasefor treating human cancers with deregulated EGFR, yet patients
frequently develop resistance (Balak et al., 2006). Several onco-
genic pathways have been shown to be involved in TKI resis-
tance, but the detailed mechanisms are not yet completed.
The current study also raises an interesting possibility that the806 Cancer Cell 23, 796–810, June 10, 2013 ª2013 Elsevier Inc.identified Lyn/ MCM7/DNA replication licensing pathway is
one of the underlying mechanisms contributing to the TKIs resis-
tance, and therefore, the Lyn-specific inhibitor may be effective
against the EGFR activating human cancers that have developed
TKI resistance and is worthy of further development.
Several posttranslational modifications have been identified in
other MCM family members and shown to be functionally impor-
tant in initiating DNA replication. Specifically, phosphorylation of
MCM2 at Ser27, Ser41, and Ser139 by CDC7/DBF4 kinase dur-
ing G1/S phase enhances the ATPase activity of MCM complex
and is essential for initiating DNA replication (Tsuji et al., 2006),
whereas phosphorylation of MCM2 at Ser5 by CDC7/DBF4
kinase promotes chromatin loading of MCM2 and MCM com-
plex assembly (Chuang et al., 2009). Additionally, cyclin-depen-
dent kinase 1 (CDK1)-dependent MCM3 phosphorylation at
Ser112 regulates its incorporation into the MCM2–MCM7 com-
plex (Lin et al., 2008) and CDK2-dependent MCM3 phosphoryla-
tion at Thr722 regulates its loading onto chromatin inmammalian
cells (Li et al., 2011). While Y600 phosphorylation that enhances
MCM7 interaction with other MCM members contributes to the
cancer cell proliferation triggered by the EGFR-Lyn signaling
axis, the nonphosphorylatable mutant MCM7 Y600F still main-
tains its basal interaction with other MCMmembers, suggesting
that MCM7 Y600F is a mutant insensitive to EGF stimulation
rather than a dominant negative mutant. Thus, the EGFR/Lyn-
mediated-MCM7 Y600 phosphorylation plays a positive regula-
tory role but not an indispensable role in the MCM7 functions.
Besides, MCM7 regulates other biological processes indepen-
dent of its DNA replication licensing function (Hubbi et al.,
2011) and other posttranslational modifications of MCM7 could
also regulate MCM7 functions in response to different mitogenic
stimuli. Further investigation would be necessary to elucidate
their biological functions.
Lyn is overexpressed in prostate cancer cells, and inhibition of
Lyn expression suppresses prostate cancer cell proliferation
(Goldenberg-Furmanov et al., 2004; Park et al., 2008). Intrigu-
ingly, while siRNA-mediated inhibition of Lyn suppresses cellular
proliferation, siRNA inhibition of Src suppresses primarily cell
migration in prostate cancer cells (Park et al., 2008). These
observations indicate that Lyn and Src may not be functionally
redundant and may regulate a different subset of substrates in
cancer cells. In the present study, we found that Lyn is necessary
for the MCM7 Y600 phosphorylation, and the expression of Lyn
but not other Src family kinases correlated significantly with the
phosphorylation level of MCM7 Y600 in both human lung tumor
tissues and breast tumor tissues, suggesting that Lyn is the pre-
dominant Src family kinase to phosphorylate MCM7 Y600. The
identification of Lyn-specific substrate, MCM7, provides ratio-
nale for the Lyn-associated cell proliferation and implies the
existence of other Lyn kinase substrates involved in cancer cell
proliferation. We predict that further elucidation of the Lyn kinase
substrates and their Tyr phosphorylation status would help us to
understand the oncogenic functions of Lyn.
An important observation in our current study is that the
activity of Lyn in MCM7 phosphorylation and cancer cell prolifer-
ation is directly regulated by EGFR-mediated Tyr phosphoryla-
tion, which suggests that Lyn may be indispensable for the
cancer cells that rely on EGFR signaling to proliferate. In sup-
port of this notion, we and others have shown that Lyn
ACB
D
E F
Figure 7. Phosphorylation of p56Lyn Y32 andMCM7 Y600 Correlate with the EGFR Protein Level of Human Tumor Samples and Poor Survival
of Breast Cancer Patients
(A) IHC staining of EGFR level and Tyr phosphorylation of p56Lyn Y32 and MCM7 Y600 of representative human breast tumor samples with high and low EGFR.
Scale bar, 25 mm.
(B) Relationship between expression of EGFR, phospho-p56Lyn Y32 (p56Lyn p-Y32), phospho-MCM7 Y600 (MCM7 p-Y600), Lyn, and MCM7 in human breast
cancer tissues.
(C) IHC staining of phospho-MCM7 Y600 and Ki-67 of representative human breast tumor samples. Scale bar, 25 mm.
(D) Relationship between expression of phospho-MCM7 Y600 and Ki-67 in human breast cancer samples.
(E) The Kaplan-Meier analysis of overall survival of breast cancer patients according to the phospho-Lyn Y32 level in their breast cancer.
(F) The Kaplan-Meier analysis of overall survival of breast cancer patients according to the phospho-MCM7 Y600 level in their breast cancer.
See also Figure S7 and Tables S2–S5.
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EGFR Potentiates MCM7 Function through Lyn Kinaseknockdown significantly compromised the proliferation of Du145
and MDA-MB-468 cells (Goldenberg-Furmanov et al., 2004),
both of which rely on EGFR signaling to proliferate (Matar
et al., 2004). In contrast, Lyn knockdown had no growth inhibi-
tory effect on certain cancer cell lines, including HCC1954, BT-
549, and MDA-MB-231 (Hochgra¨fe et al., 2010), that are less
dependent on EGFR signaling for their proliferation (Hochgra¨fe
et al., 2010; Krol et al., 2007; Sahin et al., 2009). Taken together,
the oncogenic activity of Lyn in DNA synthesis and cell prolifer-
ation is potentiated in cancer cells that depend on EGFR
signaling for their survival and targeting Lyn may demonstrate
synergistic efficacy with EGFR TKIs for treatment of this subset
of cancer cells. Given that MCM7 deregulation is frequently
associated with human cancers and tumorigenesis, these obser-
vations also provide clinical implications for the treatment of hu-
man cancers with deregulated MCM7 status using EGFR and
Lyn kinase inhibitors.EXPERIMENTAL PROCEDURES
Cell Lysates and Immunoprecipitation
Cells were collected at the indicated time, washed with ice-cold PBS, and sol-
ubilized in lysis buffer containing 1%NP-40, 25 mMNaF, 2 mMNa3VO4, 5 mM
phenylmethylsulfonyl fluoride, and 0.15 U/ml aprotinin followed by sonication.
Cell lysates were clarified by centrifugation at 16,0003 g for 20min at 4C, and
total protein concentration was determined by Bio-Rad protein assay kit using
BSA as a standard. The chromatin fraction of cell lysates was isolated
following a protocol described previously (Me´ndez and Stillman, 2000). For
each immunoprecipitation assay, 2 mg cell lysates were used and 2 mg anti-
body was added for each reaction. The reaction was rotating at 4C overnight
followed by addition of 50 ml of 50% protein A or G sepharose slurry and
rotating for 4 hr. Beads were collected and washed with PBS buffer containing
1% NP-40 three times. Immunoprecipitates were resolved by SDS-PAGE and
analyzed by immunoblotting. Free software ImageJ was used for quantifica-
tion analysis of the band density of target proteins in western blot assays.
DNA Synthesis Assay
The DNA synthesis rate was measured using the BrdU (colorimetric) ELISA kit
obtained from Roche following the manufacturer’s instructions.
Mouse Model for Tumorigenesis
In vivo cell growth was analyzed using an orthotopic breast cancer mouse
model that has been described previously (Chang et al., 1997). Briefly, 2 3
106MDA-MB-468 cells infected with lentivirus carrying the wild-type or mutant
constructs were mixed with the Matrigel (BD Biosciences) and PBS and
injected into the mammary fat pads of female nude mice. The length (L) and
width (W) of each tumor mass were measured by calipers once a week. Tumor
volume (TV) was calculated by the formula (TV = 0.53 L3W2) (Yaguchi et al.,
2006). All animal procedures were conducted under regulations of Division of
Laboratory Animal Medicine at The University of Texas MD Anderson Cancer
Center. Animal protocols (number 06-87-06139) were reviewed and approved
by the Institutional Animal Care and Use Committee at The University of Texas
MD Anderson Cancer Center.
Human Tissues
The 150 cases of surgically resected human breast cancer specimens for
immunohistochemistry and survival analysis were obtained retrospectively
from patients undergoing surgical resection of breast cancer as primary treat-
ment at The University of Texas MD Anderson Cancer Center (MDACC)
between 2000 and 2006. The specimen collection and use of human tissue
samples were conducted in accordance with the protocols approved by the
Institutional Review Board at MDACC. Written informed consent was obtained
frompatients in all cases at time of enrollment. Tissuemicroarrays of 228 cases
of breast cancer (BRC2281) and tissuemicroarrays of 228 cases of lung cancer808 Cancer Cell 23, 796–810, June 10, 2013 ª2013 Elsevier Inc.(LUC2281) were obtained from Pantomics. Tissue microarrays of 98 cases of
lung cancer (TMA IMH-305 and IMH-358) were obtained from Imgenex.
Liver Regeneration Assay
The experiment was performed using male Fisher 344 rats according to the
procedure described previously (Marti and Hug, 1995). In brief, 2/3 of rats’
livers were removed by hepatectomy under anesthesia and were sacrificed
24 hr after the operation. Both regenerated and normal liver tissues were
washed with PBS, and tissues were homogenized. The homogenized tissue
was then lysed with radioimmunoprecipitation assay buffer, and the protein
was extracted by centrifuge and used for western blot assay.
Statistical Analyses
Data were analyzed by the Student’s t test, Pearson chi-square analysis, and
Cox’s regression analysis, except Kaplan-Meier analyses on survival rates. A
p value <0.05 was considered statistically significant.
The remaining experimental procedures can be found in Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.04.027.
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